Works matching IS 03407004 AND DT 2008 AND VI 57

Results: 181
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/ neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 12, p. 1817, doi. 10.1007/s00262-008-0509-2
    By:
    • Amin, Asna;
    • Benavides, Linda C.;
    • Holmes, Jarrod P.;
    • Gates, Jeremy D.;
    • Carmichael, Mark G.;
    • Hueman, Matthew T.;
    • Mittendorf, Elizabeth A.;
    • Storrer, Catherine E.;
    • Jama, Yusuf H.;
    • Craig, Dianna;
    • Stojadinovic, Alex;
    • Ponniah, Sathibalan;
    • Peoples, George E.
    Publication type:
    Article
    10
    11
    12
    13
    14
    15

    Intratumoral immunocytokine treatment results in enhanced antitumor effects.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 12, p. 1891, doi. 10.1007/s00262-008-0519-0
    By:
    • Johnson, Erik E.;
    • Lum, Hillary D.;
    • Rakhmilevich, Alexander L.;
    • Schmidt, Brian E.;
    • Furlong, Meghan;
    • Buhtoiarov, Ilia N.;
    • Hank, Jacquelyn A.;
    • Raubitschek, Andrew;
    • Colcher, David;
    • Reisfeld, Ralph A.;
    • Gillies, Stephen D.;
    • Sondel, Paul M.
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    The “A, B and C” of Her-2 DNA vaccine development.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 11, p. 1711, doi. 10.1007/s00262-008-0464-y
    By:
    • Wei-Zen Wei;
    • Jacob, Jennifer;
    • Radkevich-Brown, Olga;
    • Whittington, Paula M.;
    • Kong, Yi-chi
    Publication type:
    Article
    27
    28
    29

    Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 11, p. 1599, doi. 10.1007/s00262-008-0491-8
    By:
    • Bennouna, Jaafar;
    • Bompas, Emmanuelle;
    • Neidhardt, Eve Marie;
    • Rolland, Frédéric;
    • Philip, Irène;
    • Galéa, Céline;
    • Salot, Samuel;
    • Saiagh, Soraya;
    • Audrain, Marie;
    • Rimbert, Marie;
    • Lafaye-de Micheaux, Sylvie;
    • Tiollier, Jérôme;
    • Négrier, Sylvie
    Publication type:
    Article
    30
    31

    Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E<sub>2</sub> results in high interleukin-12 production and cell migration.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 11, p. 1589, doi. 10.1007/s00262-008-0489-2
    By:
    • Boullart, A. C. Inge;
    • Aarntzen, Erik H. J.;
    • Verdijk, Pauline;
    • Jacobs, Joannes F. M.;
    • Schuurhuis, Danita H.;
    • Benitez-Ribas, Daniel;
    • Schreibelt, Gerty;
    • van de Rakt, Mandy W. M. M.;
    • Scharenborg, Nicole M.;
    • de Boer, Annemiek;
    • Kramer, Matthijs;
    • Figdor, Carl G.;
    • Punt, Cornelis J. A.;
    • Adema, Gosse J.;
    • de Vries, I. Jolanda M.
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46

    The E75 HER2/ neu peptide vaccine.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 10, p. 1511, doi. 10.1007/s00262-008-0540-3
    By:
    • Mittendorf, Elizabeth A.;
    • Holmes, Jarrod P.;
    • Ponniah, Sathibalan;
    • Peoples, George E.
    Publication type:
    Article
    47

    Dendritic cell vaccination and immune monitoring.

    Published in:
    Cancer Immunology, Immunotherapy, 2008, v. 57, n. 10, p. 1559, doi. 10.1007/s00262-008-0553-y
    By:
    • Aarntzen, E. H. J. G.;
    • Figdor, C. G.;
    • Adema, G. J.;
    • Punt, C. J. A.;
    • De Vries, I. J. M.
    Publication type:
    Article
    48
    49
    50